Avidity Biosciences, Inc. (RNA)
UndervaluedFundamental
38
Price
$8.20
Market Cap
$137M
Part 1 · What the company is worth
Overview
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$36M
Trailing 12 months (through 6/30/2026)
Net Income
$-93M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$-43M
Total Equity
$207M
Total Liabilities
$71M
Current Ratio
6.53
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$21.03
Current Price
$8.20
Margin of Safety
+61.0%
Fair Value Range
$14.15 - $27.91
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-37.0%
P/B Ratio
0.66
P/FCF
-
Gross Margin
-
ROIC
-25.7%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-25.7%
WACC
11.0%
ROIC − WACC
-36.7 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (5)
- P/B ratio 0.66
- Debt/equity ratio
- Current ratio
- DCF valuation (Undervalued)
- Earnings surprise, average 13.1%
Failed (8)
- EPS shows upward trend
- ROIC -25.7%
- Operating margin -412.6%
- Positive free cash flow
- ROE -40.3%
- Share dilution 54.8%
- Net margin trend -411.9% vs -230.5%
- Piotroski F-Score 4/9
Unavailable (13)
- Historical price data insufficient
- Gross margin –
- P/FCF –
- Dividend payout –
- CapEx intensity
- Interest coverage
- Debt/EBITDA
- Return on tangible assets
- Low reliance on intangibles
- Price below Graham Number
- Revenue growth 5Y
- PEG ratio (needs P/E > 0 and growth > 0)
- Earnings quality (operating cash flow / net income)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
Low quality: investigate accounting
Share Dilution
Issuing new shares, diluting ownership
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Ms. Kathleen P. Gallagher | President, CEO & Director | 44 |
| Mr. Brendan Winslow | Chief Financial Officer | 37 |
| Dr. Husam Younis Ph.D., Pharm.D. | Chief Scientific Officer | 51 |
| Ms. Stephanie Kenney | Chief Corporate Affairs Officer | 47 |
| Dr. Steven George Hughes M.B.A., M.D. | Chief Medical Officer | 58 |
| Ms. Rocio Martin Hoyos | Chief Strategy Officer | 42 |
Documents
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-13
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-10-08
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much RNA moves, measured on its daily prices.
More volatile than 84% of the tracked stocks (90-day volatility).
- Volatility 30d
- 50.9%
- Volatility 90d
- 57.8%
- Beta vs S&P 500 (1y)
- —
- Max drawdown (12m)
- —
- ATR (14d, % of price)
- 5.35%
Earnings reactions
How RNA moved around its past quarterly results.
Next earnings release
Nov 9, 2026 · In 16 days · Time not known
EPS estimate: -0.63Revenue estimate: $12M
What usually happens
- Not enough releases with data yet: we have 2, we need at least 4.
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | After the close | -1.43 | -1.18 | +17.6% | -1.0% | +4.1% | +9.3% |
| May 14, 2026 | After the close | -1.06 | -0.97 | +8.5% | +1.6% | -0.3% | -1.7% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on RNA and what the price did next.
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for RNA.